Pub Date : 2026-01-15DOI: 10.1007/s00431-025-06702-8
Sohier Yahia, Zahraa Abdelmoneim, Dina Ghozzy, Yahya Wahba, Hany M Abo-Haded
Neurofibromatosis type 1 (NF1) is an autosomal dominant syndrome caused by mutations in the NF1 gene. Although cardiac abnormalities have been observed in NF1, they are frequently overlooked due to a lack of routine cardiac surveillance. Myocardial strain imaging offers a sensitive and non-invasive method for detecting early subclinical myocardial dysfunction. This study aims to detect cardiac abnormalities in children with NF1 using conventional echocardiography, Doppler tissue imaging (DTI), and myocardial strain analysis. A case-control study was conducted on 38 asymptomatic children with clinically confirmed NF1 and 35 healthy, age- and sex-matched controls. All patients underwent ECG, conventional echocardiography, DTI, and two-dimensional speckle-tracking echocardiography. NF1 patients showed significantly decreased ejection fraction (p = 0.0009) and higher interventricular septal and posterior wall thickness during systole (p < 0.0001). DTI revealed reduced mitral systolic (Sm) and early diastolic (Em) velocities, longer isovolumic contraction and relaxation periods, and increased LV Tei index values (p < 0.0001), indicating combined systolic and diastolic dysfunction. Also, myocardial strain analysis in NF1 children revealed considerably lower peak systolic left ventricular global longitudinal strain (LVGLS) (p 0.0014), as well as lower peak systolic septal and lateral wall strain values (p 0.0046, 0.0027), respectively. Conclusion: Children with NF1 show early subclinical myocardial dysfunction, even when there is no hypertension or overt cardiac symptoms. These findings highlight the significance of frequent echocardiographic screening, including strain imaging, for the early diagnosis and longitudinal monitoring of heart function in NF1 children. What is Known: • Neurofibromatosis type 1 (NF1) is a multisystem syndrome that can involve the cardiovascular system. • Previous studies showed hypertrophic cardiac changes in NF1 patients, but data in children, especially those without hypertension, are limited, as routine echocardiography is not involved in NF1 management. What is New: • Our study revealed early subclinical myocardial dysfunction in NF1 children without the presence of hypertension or overt cardiac symptoms. • This emphasizes the potential of myocardial strain imaging as a sensitive tool for early detection of myocardial dysfunction in NF1 children, thereby supporting the need for routine echocardiographic surveillance in these patients.
{"title":"Unraveling cardiac anomalies in pediatric neurofibromatosis type 1: insights and implications.","authors":"Sohier Yahia, Zahraa Abdelmoneim, Dina Ghozzy, Yahya Wahba, Hany M Abo-Haded","doi":"10.1007/s00431-025-06702-8","DOIUrl":"10.1007/s00431-025-06702-8","url":null,"abstract":"<p><p>Neurofibromatosis type 1 (NF1) is an autosomal dominant syndrome caused by mutations in the NF1 gene. Although cardiac abnormalities have been observed in NF1, they are frequently overlooked due to a lack of routine cardiac surveillance. Myocardial strain imaging offers a sensitive and non-invasive method for detecting early subclinical myocardial dysfunction. This study aims to detect cardiac abnormalities in children with NF1 using conventional echocardiography, Doppler tissue imaging (DTI), and myocardial strain analysis. A case-control study was conducted on 38 asymptomatic children with clinically confirmed NF1 and 35 healthy, age- and sex-matched controls. All patients underwent ECG, conventional echocardiography, DTI, and two-dimensional speckle-tracking echocardiography. NF1 patients showed significantly decreased ejection fraction (p = 0.0009) and higher interventricular septal and posterior wall thickness during systole (p < 0.0001). DTI revealed reduced mitral systolic (Sm) and early diastolic (Em) velocities, longer isovolumic contraction and relaxation periods, and increased LV Tei index values (p < 0.0001), indicating combined systolic and diastolic dysfunction. Also, myocardial strain analysis in NF1 children revealed considerably lower peak systolic left ventricular global longitudinal strain (LVGLS) (p 0.0014), as well as lower peak systolic septal and lateral wall strain values (p 0.0046, 0.0027), respectively. Conclusion: Children with NF1 show early subclinical myocardial dysfunction, even when there is no hypertension or overt cardiac symptoms. These findings highlight the significance of frequent echocardiographic screening, including strain imaging, for the early diagnosis and longitudinal monitoring of heart function in NF1 children. What is Known: • Neurofibromatosis type 1 (NF1) is a multisystem syndrome that can involve the cardiovascular system. • Previous studies showed hypertrophic cardiac changes in NF1 patients, but data in children, especially those without hypertension, are limited, as routine echocardiography is not involved in NF1 management. What is New: • Our study revealed early subclinical myocardial dysfunction in NF1 children without the presence of hypertension or overt cardiac symptoms. • This emphasizes the potential of myocardial strain imaging as a sensitive tool for early detection of myocardial dysfunction in NF1 children, thereby supporting the need for routine echocardiographic surveillance in these patients.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"79"},"PeriodicalIF":2.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12808207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Intra-amniotic inflammation and infection are common intrapartum conditions at term and represent a major cause of fetal and neonatal morbidity independent of hypoxia. These conditions trigger the fetal inflammatory response syndrome (FIRS), characterized by systemic cytokine activation, cardiovascular dysfunction, impaired thermoregulation, and neuroinflammation, which substantially increase the risk of early-onset neonatal sepsis, encephalopathy, and long-term neurological injury. The coexistence of inflammation and intrapartum hypoxic stress markedly amplifies fetal brain vulnerability. During labor, fetal inflammation is associated with specific cardiotocographic patterns that may precede metabolic acidemia. Early signs include unexplained fetal tachycardia or a progressive rise in baseline heart rate, often without preceding decelerations. With progression, loss of accelerations, abnormalities of baseline variability-including increased, reduced, or atypical sinusoidal patterns-and absence of sleep-wake cycling become evident. Decelerations may develop secondary to inflammation-related placental dysfunction, altered umbilical blood flow, and abnormal uterine contractility.
Conclusion: Prompt recognition of these intrapartum features allows early intervention through maternal temperature control, antibiotic therapy, and timely delivery when indicated. Early identification and management of fetal inflammation are essential to mitigate inflammation-mediated neonatal morbidity and adverse neurological outcomes.
What is known: • Intra-amniotic inflammation and infection during labor are common at term and are major contributors to fetal and neonatal morbidity. • Traditional intrapartum cardiotocography (CTG) interpretation is primarily focused on detecting hypoxia-related fetal compromise and may fail to recognize non-hypoxic inflammatory insults.
What is new: • Fetal exposure to intra-amniotic inflammation during labor can be identified antenatally through specific intrapartum cardiotocographic patterns, even in the absence of maternal clinical signs of infection. • The recognition of CTG features suggestive of fetal inflammation provides an opportunity for earlier intrapartum intervention, with potential to reduce neonatal sepsis, encephalopathy, and long-term neurological injury.
{"title":"Intrapartum recognition and management of fetal inflammation.","authors":"Elvira di Pasquo, Susana Pereira, Beatrice Valentini, Alessandra Familiari, Tullio Ghi","doi":"10.1007/s00431-025-06738-w","DOIUrl":"https://doi.org/10.1007/s00431-025-06738-w","url":null,"abstract":"<p><p>Intra-amniotic inflammation and infection are common intrapartum conditions at term and represent a major cause of fetal and neonatal morbidity independent of hypoxia. These conditions trigger the fetal inflammatory response syndrome (FIRS), characterized by systemic cytokine activation, cardiovascular dysfunction, impaired thermoregulation, and neuroinflammation, which substantially increase the risk of early-onset neonatal sepsis, encephalopathy, and long-term neurological injury. The coexistence of inflammation and intrapartum hypoxic stress markedly amplifies fetal brain vulnerability. During labor, fetal inflammation is associated with specific cardiotocographic patterns that may precede metabolic acidemia. Early signs include unexplained fetal tachycardia or a progressive rise in baseline heart rate, often without preceding decelerations. With progression, loss of accelerations, abnormalities of baseline variability-including increased, reduced, or atypical sinusoidal patterns-and absence of sleep-wake cycling become evident. Decelerations may develop secondary to inflammation-related placental dysfunction, altered umbilical blood flow, and abnormal uterine contractility.</p><p><strong>Conclusion: </strong> Prompt recognition of these intrapartum features allows early intervention through maternal temperature control, antibiotic therapy, and timely delivery when indicated. Early identification and management of fetal inflammation are essential to mitigate inflammation-mediated neonatal morbidity and adverse neurological outcomes.</p><p><strong>What is known: </strong>• Intra-amniotic inflammation and infection during labor are common at term and are major contributors to fetal and neonatal morbidity. • Traditional intrapartum cardiotocography (CTG) interpretation is primarily focused on detecting hypoxia-related fetal compromise and may fail to recognize non-hypoxic inflammatory insults.</p><p><strong>What is new: </strong>• Fetal exposure to intra-amniotic inflammation during labor can be identified antenatally through specific intrapartum cardiotocographic patterns, even in the absence of maternal clinical signs of infection. • The recognition of CTG features suggestive of fetal inflammation provides an opportunity for earlier intrapartum intervention, with potential to reduce neonatal sepsis, encephalopathy, and long-term neurological injury.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"81"},"PeriodicalIF":2.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15DOI: 10.1007/s00431-025-06679-4
Anna Stage, Emil Buch Fromberg, Peter Elsborg, Mette Røn Kristensen, Silje Mikkelsen, Mads Bølling, Mette Aadahl, Michelle Stahlhut
To assess the validity of the SENS motion® system (SENS) for measuring postures and movements in school-aged children with functional disabilities, using direct video observation as the criterion method. In this cross-sectional-study, 29 children (51.7% male, mean age 10.8 ± 2.9 years) from two special schools in Denmark participated. Each child wore a SENS device on the thigh while completing a standardized protocol of six categories: lying/sitting, standing, walking, running, cycling, and step count. All activities were video recorded. Video data were coded in 5-s epochs and aligned with SENS output. Agreement was assessed by comparing the observed time spent in each activity with the corresponding time estimated by SENS, expressed as mean values, standard deviations, mean differences, and percentage agreement. SENS showed excellent agreement for walking (93.2%) and lying/sitting (96.2%), good agreement for running (89.2%), and moderate agreement for standing (74.1%). Cycling was poorly detected, with only 6.4% agreement, as it was frequently misclassified as walking (50.8%) or lying/sitting (42.7%). Step counts were slightly overestimated by SENS (mean difference 7.2 steps). Overall, SENS tended to underestimate activity duration compared with the observation.
Conclusion: SENS demonstrated excellent to good validity for detecting lying/sitting, walking, and acceptable validity for running in children with functional disabilities, but moderate validity for standing and limited validity for cycling. These findings indicate that SENS may be useful for monitoring several common postures and activities in this population, though further algorithm refinement and broader validation are needed, particularly for cycling and postural transitions.
What is known: • Children with disabilities engage in less dynamic postures and more lying/sitting time than their peers without disabilities. • Accelerometer systems are typically validated in healthy populations, limiting accuracy in children with disabilities.
What is new: • SENS shows excellent to good validity for lying/sitting, walking, and running in children with functional disabilities. • SENS performs poorly for cycling and moderately for standing, highlighting the need for algorithm refinement.
{"title":"Validation of an accelerometer system for activity monitoring in children with functional disabilities.","authors":"Anna Stage, Emil Buch Fromberg, Peter Elsborg, Mette Røn Kristensen, Silje Mikkelsen, Mads Bølling, Mette Aadahl, Michelle Stahlhut","doi":"10.1007/s00431-025-06679-4","DOIUrl":"10.1007/s00431-025-06679-4","url":null,"abstract":"<p><p>To assess the validity of the SENS motion® system (SENS) for measuring postures and movements in school-aged children with functional disabilities, using direct video observation as the criterion method. In this cross-sectional-study, 29 children (51.7% male, mean age 10.8 ± 2.9 years) from two special schools in Denmark participated. Each child wore a SENS device on the thigh while completing a standardized protocol of six categories: lying/sitting, standing, walking, running, cycling, and step count. All activities were video recorded. Video data were coded in 5-s epochs and aligned with SENS output. Agreement was assessed by comparing the observed time spent in each activity with the corresponding time estimated by SENS, expressed as mean values, standard deviations, mean differences, and percentage agreement. SENS showed excellent agreement for walking (93.2%) and lying/sitting (96.2%), good agreement for running (89.2%), and moderate agreement for standing (74.1%). Cycling was poorly detected, with only 6.4% agreement, as it was frequently misclassified as walking (50.8%) or lying/sitting (42.7%). Step counts were slightly overestimated by SENS (mean difference 7.2 steps). Overall, SENS tended to underestimate activity duration compared with the observation.</p><p><strong>Conclusion: </strong> SENS demonstrated excellent to good validity for detecting lying/sitting, walking, and acceptable validity for running in children with functional disabilities, but moderate validity for standing and limited validity for cycling. These findings indicate that SENS may be useful for monitoring several common postures and activities in this population, though further algorithm refinement and broader validation are needed, particularly for cycling and postural transitions.</p><p><strong>What is known: </strong>• Children with disabilities engage in less dynamic postures and more lying/sitting time than their peers without disabilities. • Accelerometer systems are typically validated in healthy populations, limiting accuracy in children with disabilities.</p><p><strong>What is new: </strong>• SENS shows excellent to good validity for lying/sitting, walking, and running in children with functional disabilities. • SENS performs poorly for cycling and moderately for standing, highlighting the need for algorithm refinement.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"78"},"PeriodicalIF":2.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12808203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><p>Childhood obesity is the main driver of early metabolic risk, predisposing to cardiovascular disease (CVD) and type 2 diabetes (T2D), which cause millions of deaths worldwide. Their progression is influenced by biological, behavioral, and environmental factors. Digital Twin Systems (DTS) offer innovative ways to monitor and predict cardiometabolic risk. This work presents a prototype digital twin platform called PODiaCarD designed for managing pediatric obesity and related cardiometabolic complications. The system integrates clinical, anthropometric, and lifestyle data with machine learning to estimate outcomes in youth. Built on a three-layer architecture (frontend, backend, predictive engine), PODiaCarD ensures scalability, observability, and reproducibility while enabling continuous model improvement. Models, trained on the PODiaCar project dataset (n = 552, 12.2 ± 2.9 years) with cross-validation and target-specific algorithms, predict eight key metabolic outcomes. The infrastructure follows privacy-by-design and GDPR standards, ensuring security, auditability, and clinical compliance. PODiaCarD achieved excellent performance for TyG index (F1 = 0.975 ± 0.014, random forest) and solid results for HbA1C (F1 = 0.844 ± 0.028, random forest). Moderate accuracy was observed for HOMA (F1 = 0.670 ± 0.070, Gradient Boosting). In contrast, models for blood pressure (R<sup>2</sup> = 0.05-0.21; F1 = 0.446 ± 0.045) and glycemia (F1 = 0.113 ± 0.113) showed poor predictive capacity, while insulin regression (R<sup>2</sup> = 0.211) remained limited, highlighting the need for richer datasets.</p><p><strong>Conclusions: </strong> PODiaCarD is a promising tool for managing pediatric obesity and complications. It integrates clinical, anthropometric, and behavioral data with ML-based models to support pediatricians in early risk detection, dynamic monitoring, and personalized prevention. Its federated design allows continuous dataset growth and improved predictive performance, strengthening its role in pediatric cardiometabolic care.</p><p><strong>What is known: </strong>• Pediatric obesity is a major early driver of cardiometabolic risk; body mass index, waist circumference, and lipid profile are key indicators of insulin resistance, type 2 diabetes, and cardiovascular diseases. Existing pediatric predictive models are often static and limited in longitudinal integration. • Digital Twin Systems enable dynamic monitoring and "what-if" simulations in healthcare, but cardiometabolic applications in pediatric populations remain scarce and insufficiently validated.</p><p><strong>What is new: </strong>• PODiaCarD introduces a federated pediatric digital twin that integrates clinical, anthropometric, and lifestyle data with machine learning to dynamically update individual cardiometabolic risk profiles over time. • The platform achieves strong performance for insulin resistance surrogates and HbA1c prediction, provides explainable AI outputs, ensures privacy-by-
{"title":"PODiaCarD: a prototype of a digital twin platform for the management of pediatric obesity and related cardiometabolic complications.","authors":"Valeria Calcaterra, Umberto Ciriello, Samuele Medici, Valter Pagani, Cristina Campoy, Lucia Labati, Virginia Rossi, Mireia Escudero-Marin, Matteo Vandoni, Camilo Corbellini, Elvira Verduci, Luca Marin, Rocio Bonillo-Leon, Khatija Bahdur, Alessandro Gatti, Giulia Fiore, Vittoria Carnevale Pellino, Savina Mannarino, Gianvincenzo Zuccotti","doi":"10.1007/s00431-025-06708-2","DOIUrl":"https://doi.org/10.1007/s00431-025-06708-2","url":null,"abstract":"<p><p>Childhood obesity is the main driver of early metabolic risk, predisposing to cardiovascular disease (CVD) and type 2 diabetes (T2D), which cause millions of deaths worldwide. Their progression is influenced by biological, behavioral, and environmental factors. Digital Twin Systems (DTS) offer innovative ways to monitor and predict cardiometabolic risk. This work presents a prototype digital twin platform called PODiaCarD designed for managing pediatric obesity and related cardiometabolic complications. The system integrates clinical, anthropometric, and lifestyle data with machine learning to estimate outcomes in youth. Built on a three-layer architecture (frontend, backend, predictive engine), PODiaCarD ensures scalability, observability, and reproducibility while enabling continuous model improvement. Models, trained on the PODiaCar project dataset (n = 552, 12.2 ± 2.9 years) with cross-validation and target-specific algorithms, predict eight key metabolic outcomes. The infrastructure follows privacy-by-design and GDPR standards, ensuring security, auditability, and clinical compliance. PODiaCarD achieved excellent performance for TyG index (F1 = 0.975 ± 0.014, random forest) and solid results for HbA1C (F1 = 0.844 ± 0.028, random forest). Moderate accuracy was observed for HOMA (F1 = 0.670 ± 0.070, Gradient Boosting). In contrast, models for blood pressure (R<sup>2</sup> = 0.05-0.21; F1 = 0.446 ± 0.045) and glycemia (F1 = 0.113 ± 0.113) showed poor predictive capacity, while insulin regression (R<sup>2</sup> = 0.211) remained limited, highlighting the need for richer datasets.</p><p><strong>Conclusions: </strong> PODiaCarD is a promising tool for managing pediatric obesity and complications. It integrates clinical, anthropometric, and behavioral data with ML-based models to support pediatricians in early risk detection, dynamic monitoring, and personalized prevention. Its federated design allows continuous dataset growth and improved predictive performance, strengthening its role in pediatric cardiometabolic care.</p><p><strong>What is known: </strong>• Pediatric obesity is a major early driver of cardiometabolic risk; body mass index, waist circumference, and lipid profile are key indicators of insulin resistance, type 2 diabetes, and cardiovascular diseases. Existing pediatric predictive models are often static and limited in longitudinal integration. • Digital Twin Systems enable dynamic monitoring and \"what-if\" simulations in healthcare, but cardiometabolic applications in pediatric populations remain scarce and insufficiently validated.</p><p><strong>What is new: </strong>• PODiaCarD introduces a federated pediatric digital twin that integrates clinical, anthropometric, and lifestyle data with machine learning to dynamically update individual cardiometabolic risk profiles over time. • The platform achieves strong performance for insulin resistance surrogates and HbA1c prediction, provides explainable AI outputs, ensures privacy-by-","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"77"},"PeriodicalIF":2.6,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1007/s00431-025-06725-1
Nora C Carpay, Kim Kamphorst, Arine M Vlieger, Ruurd M van Elburg
Dysbiosis in early life has been associated with the development of atopic diseases. In the INCA study, antibiotic treatment in the first week of life was associated with wheezing at 1 year and food allergies at 4-6 years. This follow-up study investigates whether these associations persist at age 9-12, and whether new associations with other atopic diseases have developed. The INCA cohort consisted of 436 children included in 2012-2015 to investigate the long-term effects of antibiotic treatment in the first week of life. Term-born infants from four Dutch hospitals were included, of which 151 received intravenous antibiotics in their first week of life due to suspected early-onset sepsis (AB+), and 285 were unexposed infants (AB-). In the 9-12-year follow-up study, parents and children filled out questionnaires on atopic diseases. Furthermore, general practitioners' diagnoses were collected. The follow-up questionnaire was completed by 314 participants. Parental-reported and test-confirmed food allergies were more prevalent in AB+ children compared to AB- (unadjusted odds ratio (OR) 3.52, 95% confidence interval (CI) 1.50-8.25 and OR 6.6, 95% CI 1.3-32, respectively). However, no significant differences existed between AB+ and AB- in the incidence of asthma (OR 0.73, 95% CI 0.25-2.1) or inhalant allergies (OR 1.03, 95% CI 0.554-1.91). The "any allergy" diagnosis by general practitioners was more prevalent in AB+ than AB- (OR 3.0, 95% CI 1.2-7.6).
Conclusions: Antibiotic treatment in the first week of life is associated with food allergies at ages 9-12, but not with asthma, inhalant allergies, or eczema.
What is known: • Correlations have been observed between early life antibiotics exposure (< 2 years of age) and the development of atopic diseases such as asthma, eczema, and allergies. • Antibiotics exposure specifically in the first week of life has been associated with an increased risk of wheezing at age 1 and food allergies at ages 4-6.
What is new: • Antibiotics in the first week of life are still associated with food allergies at ages 9-12, but not with airway atopy (asthma, hay fever, or inhalant allergies). • The results of this study suggest that there may be different mechanisms involved in the development of food vs. inhalant allergies, and further research is needed to determine how these diseases develop and how to prevent this.
生命早期的生态失调与特应性疾病的发展有关。在INCA的研究中,出生后第一周的抗生素治疗与1岁时的喘息和4-6岁时的食物过敏有关。这项后续研究调查了这些关联是否在9-12岁时持续存在,以及是否与其他特应性疾病产生了新的关联。INCA队列包括2012-2015年纳入的436名儿童,以调查生命第一周抗生素治疗的长期影响。研究纳入了来自荷兰四家医院的足月婴儿,其中151名因疑似早发性败血症(AB+)而在出生后第一周接受静脉注射抗生素,285名未接触抗生素的婴儿(AB-)。在9-12年的随访研究中,父母和孩子填写了有关特应性疾病的问卷。此外,收集全科医生的诊断。314名参与者完成了随访问卷。父母报告和测试证实的食物过敏在AB+儿童中比AB-儿童更普遍(未调整比值比(OR) 3.52, 95%置信区间(CI) 1.50-8.25, OR 6.6, 95% CI 1.3-32)。然而,AB+和AB-在哮喘(OR 0.73, 95% CI 0.25-2.1)或吸入性过敏(OR 1.03, 95% CI 0.554-1.91)的发生率上没有显著差异。全科医生的“任何过敏”诊断在AB+中比AB-更普遍(OR 3.0, 95% CI 1.2-7.6)。结论:出生第一周的抗生素治疗与9-12岁的食物过敏有关,但与哮喘、吸入性过敏或湿疹无关。•观察到生命早期抗生素暴露之间的相关性(新发现:•生命第一周的抗生素仍然与9-12岁的食物过敏有关,但与气道特应性(哮喘,花粉热或吸入性过敏)无关。•这项研究的结果表明,食物过敏和吸入物过敏的发展可能有不同的机制,需要进一步的研究来确定这些疾病是如何发展的,以及如何预防。
{"title":"Antibiotics in the first week of life and the association with atopic diseases at ages 9-12: a prospective cohort study.","authors":"Nora C Carpay, Kim Kamphorst, Arine M Vlieger, Ruurd M van Elburg","doi":"10.1007/s00431-025-06725-1","DOIUrl":"10.1007/s00431-025-06725-1","url":null,"abstract":"<p><p>Dysbiosis in early life has been associated with the development of atopic diseases. In the INCA study, antibiotic treatment in the first week of life was associated with wheezing at 1 year and food allergies at 4-6 years. This follow-up study investigates whether these associations persist at age 9-12, and whether new associations with other atopic diseases have developed. The INCA cohort consisted of 436 children included in 2012-2015 to investigate the long-term effects of antibiotic treatment in the first week of life. Term-born infants from four Dutch hospitals were included, of which 151 received intravenous antibiotics in their first week of life due to suspected early-onset sepsis (AB+), and 285 were unexposed infants (AB-). In the 9-12-year follow-up study, parents and children filled out questionnaires on atopic diseases. Furthermore, general practitioners' diagnoses were collected. The follow-up questionnaire was completed by 314 participants. Parental-reported and test-confirmed food allergies were more prevalent in AB+ children compared to AB- (unadjusted odds ratio (OR) 3.52, 95% confidence interval (CI) 1.50-8.25 and OR 6.6, 95% CI 1.3-32, respectively). However, no significant differences existed between AB+ and AB- in the incidence of asthma (OR 0.73, 95% CI 0.25-2.1) or inhalant allergies (OR 1.03, 95% CI 0.554-1.91). The \"any allergy\" diagnosis by general practitioners was more prevalent in AB+ than AB- (OR 3.0, 95% CI 1.2-7.6).</p><p><strong>Conclusions: </strong> Antibiotic treatment in the first week of life is associated with food allergies at ages 9-12, but not with asthma, inhalant allergies, or eczema.</p><p><strong>What is known: </strong>• Correlations have been observed between early life antibiotics exposure (< 2 years of age) and the development of atopic diseases such as asthma, eczema, and allergies. • Antibiotics exposure specifically in the first week of life has been associated with an increased risk of wheezing at age 1 and food allergies at ages 4-6.</p><p><strong>What is new: </strong>• Antibiotics in the first week of life are still associated with food allergies at ages 9-12, but not with airway atopy (asthma, hay fever, or inhalant allergies). • The results of this study suggest that there may be different mechanisms involved in the development of food vs. inhalant allergies, and further research is needed to determine how these diseases develop and how to prevent this.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"76"},"PeriodicalIF":2.6,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1007/s00431-025-06740-2
Bianca van Vreeswijk, Sijmen A Reijneveld, Netty Bos-Veneman
Childhood vaccination is a very effective public health intervention. Fear of pain during vaccination reduces vaccine willingness and can be addressed by interventions. We aimed to identify behavioural determinants of the use of pain-reducing interventions by Preventive Child Healthcare (PCH) physicians and nurses and the associations of sociodemographic characteristics with these behavioural determinants. We invited all PCH professionals of one municipal health service (Groningen, the Netherlands; n = 180) to fill in an online questionnaire on behavioural determinants of the use of pain-reducing interventions, based on the ASE (Attitude-Social influence-self-Efficacy) model of behaviour. We evaluated the associations of their background characteristics with their responses using logistic regression analyses. Of the 83 PCH professionals, 95% considered it important to reduce pain during vaccination, 90% intended to liaise with children and parents about pain mitigation, and 85% reported a high self-efficacy regarding the use of pain-reducing interventions. Lack of time and knowledge about pain reduction, and difficulties in the use of pain mitigation were negatively associated with the use of pain-reducing interventions. Nurses were more likely than physicians to liaise with children and parents about pain mitigation during vaccination (odds ratio, 95% confidence interval 8.86, 1.62 to 48.4) and believe they are competent to mitigate pain during vaccination (6.27, 1.65 to 23.9).
Conclusion: Most PCH professionals acknowledge the importance of reducing pain during vaccination but experience various barriers in the use of pain-reducing interventions. Education of professionals might contribute to the adherence to guidelines regarding pain reduction.
What is known: • Childhood vaccination is a very effective public health intervention. • Fear of pain during vaccination reduces vaccine willingness and can be addressed by interventions.
What is new: • Most Preventive Child Healthcare physicians and nurses acknowledge the importance of reducing pain during vaccination but experience various barriers in the use of pain-reducing interventions. • Education of professionals might contribute to the adherence to guidelines regarding pain reduction.
{"title":"Behavioural determinants of the use of pain-reducing interventions-a survey among professionals who vaccinate children.","authors":"Bianca van Vreeswijk, Sijmen A Reijneveld, Netty Bos-Veneman","doi":"10.1007/s00431-025-06740-2","DOIUrl":"10.1007/s00431-025-06740-2","url":null,"abstract":"<p><p>Childhood vaccination is a very effective public health intervention. Fear of pain during vaccination reduces vaccine willingness and can be addressed by interventions. We aimed to identify behavioural determinants of the use of pain-reducing interventions by Preventive Child Healthcare (PCH) physicians and nurses and the associations of sociodemographic characteristics with these behavioural determinants. We invited all PCH professionals of one municipal health service (Groningen, the Netherlands; n = 180) to fill in an online questionnaire on behavioural determinants of the use of pain-reducing interventions, based on the ASE (Attitude-Social influence-self-Efficacy) model of behaviour. We evaluated the associations of their background characteristics with their responses using logistic regression analyses. Of the 83 PCH professionals, 95% considered it important to reduce pain during vaccination, 90% intended to liaise with children and parents about pain mitigation, and 85% reported a high self-efficacy regarding the use of pain-reducing interventions. Lack of time and knowledge about pain reduction, and difficulties in the use of pain mitigation were negatively associated with the use of pain-reducing interventions. Nurses were more likely than physicians to liaise with children and parents about pain mitigation during vaccination (odds ratio, 95% confidence interval 8.86, 1.62 to 48.4) and believe they are competent to mitigate pain during vaccination (6.27, 1.65 to 23.9).</p><p><strong>Conclusion: </strong> Most PCH professionals acknowledge the importance of reducing pain during vaccination but experience various barriers in the use of pain-reducing interventions. Education of professionals might contribute to the adherence to guidelines regarding pain reduction.</p><p><strong>What is known: </strong>• Childhood vaccination is a very effective public health intervention. • Fear of pain during vaccination reduces vaccine willingness and can be addressed by interventions.</p><p><strong>What is new: </strong>• Most Preventive Child Healthcare physicians and nurses acknowledge the importance of reducing pain during vaccination but experience various barriers in the use of pain-reducing interventions. • Education of professionals might contribute to the adherence to guidelines regarding pain reduction.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"74"},"PeriodicalIF":2.6,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12795855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1007/s00431-025-06731-3
Fuzhi Lin, Yufei Peng, Xiaowei Chen, Wei Wu, Yong Fu
Early identification of children at high risk for moderate-to-severe obstructive sleep apnea (OSA) is crucial for timely intervention, yet is often hindered by limited access to polysomnography (PSG). We aimed to develop an interpretable clinical prediction model using easily obtainable clinical and inflammatory biomarkers to distinguish moderate-to-severe from mild pediatric OSA. We conducted a retrospective study of 164 children diagnosed with OSA by PSG. From multiple biomarkers and clinical variables, least absolute shrinkage and selection operator (LASSO) regression was employed to select the most predictive features. A multivariable logistic regression model was built and presented as an interpretable nomogram. Model performance was evaluated via bootstrap validation assessing discrimination, calibration, and clinical utility. The LASSO algorithm identified eight core predictors: female, tonsil size grades 3 and 4, adenoid-to-nasopharynx ratio (A/N ratio), IgE, IL-4, IL-6, and IL-10. The final model demonstrated robust performance, with a bootstrap-corrected AUC of 0.763 (95%CI 0.690-0.836). Decision curve analysis confirmed the model's clinical utility.
Conclusion: We developed an explainable nomogram that integrates upper airway anatomy, allergic, sex, and specific inflammatory cytokines. This tool provides clinicians with a practical, non-invasive method for individualized risk assessment, facilitating the identification of children with moderate-to-severe OSA who may benefit from prioritized diagnosis and intervention.
What is known: • Polysomnography(PSG) is the gold standard for diagnosing pediatric obstructive sleep apnea (OSA) but has limited accessibility, hindering the early identification of children at risk for moderate-to-severe disease.
What is new: • We developed an explainable nomogram that integrates sex, tonsil size, adenoid hypertrophy, allergy (IgE), and specific inflammatory cytokines (IL-4, IL-6, IL-10) to provide a practical, noninvasive tool for individualized risk assessment of moderate-to-severe OSA in children.
{"title":"Development of an explainable prediction model for the risk of moderate-to-severe obstructive sleep apnea in children.","authors":"Fuzhi Lin, Yufei Peng, Xiaowei Chen, Wei Wu, Yong Fu","doi":"10.1007/s00431-025-06731-3","DOIUrl":"https://doi.org/10.1007/s00431-025-06731-3","url":null,"abstract":"<p><p>Early identification of children at high risk for moderate-to-severe obstructive sleep apnea (OSA) is crucial for timely intervention, yet is often hindered by limited access to polysomnography (PSG). We aimed to develop an interpretable clinical prediction model using easily obtainable clinical and inflammatory biomarkers to distinguish moderate-to-severe from mild pediatric OSA. We conducted a retrospective study of 164 children diagnosed with OSA by PSG. From multiple biomarkers and clinical variables, least absolute shrinkage and selection operator (LASSO) regression was employed to select the most predictive features. A multivariable logistic regression model was built and presented as an interpretable nomogram. Model performance was evaluated via bootstrap validation assessing discrimination, calibration, and clinical utility. The LASSO algorithm identified eight core predictors: female, tonsil size grades 3 and 4, adenoid-to-nasopharynx ratio (A/N ratio), IgE, IL-4, IL-6, and IL-10. The final model demonstrated robust performance, with a bootstrap-corrected AUC of 0.763 (95%CI 0.690-0.836). Decision curve analysis confirmed the model's clinical utility.</p><p><strong>Conclusion: </strong> We developed an explainable nomogram that integrates upper airway anatomy, allergic, sex, and specific inflammatory cytokines. This tool provides clinicians with a practical, non-invasive method for individualized risk assessment, facilitating the identification of children with moderate-to-severe OSA who may benefit from prioritized diagnosis and intervention.</p><p><strong>What is known: </strong>• Polysomnography(PSG) is the gold standard for diagnosing pediatric obstructive sleep apnea (OSA) but has limited accessibility, hindering the early identification of children at risk for moderate-to-severe disease.</p><p><strong>What is new: </strong>• We developed an explainable nomogram that integrates sex, tonsil size, adenoid hypertrophy, allergy (IgE), and specific inflammatory cytokines (IL-4, IL-6, IL-10) to provide a practical, noninvasive tool for individualized risk assessment of moderate-to-severe OSA in children.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"75"},"PeriodicalIF":2.6,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of this study is to systematically compare binocular gaming with conventional occlusion therapy for visual acuity improvement in childhood amblyopia. We conducted a systematic review and meta-analysis according to PRISMA 2020 guidelines (PROSPERO CRD420251080735). PubMed, Scopus, Cochrane Library, and Google Scholar were searched through June 2025 for randomized controlled trials in children aged 3-18 years with unilateral amblyopia. The primary outcome was best-corrected visual acuity improvement, expressed as standardized mean difference (SMD). A random-effects model was applied with subgroup analyses by treatment duration, sample size, and patient characteristics. Nine RCTs, including 986 children, met the inclusion criteria. Pooled analysis showed no significant difference between binocular gaming and patching (SMD 0.05, 95% CI - 0.2 to 0.3, p = 0.68) with substantial heterogeneity (I2 = 65%). Subgroup analyses revealed time-dependent effects: short-duration trials (≤ 6 weeks) favored binocular gaming (SMD 0.35, 95% CI 0.05-0.65, p = 0.02), medium-duration trials (8-12 weeks) showed no significant benefit, while long-duration trials (> 12 weeks) favored patching (SMD - 0.47, 95% CI - 0.72 to - 0.22, p < 0.001). Larger, high-quality trials consistently supported patching. Publication bias analysis indicated small-study effects, with trim-and-fill suggesting the true effect may favor patching (adjusted SMD - 0.15).
Conclusion: Binocular gaming may provide short-term benefits, but robust evidence indicates patching is superior for long-term outcomes. After adequate refractive correction, conventional occlusion therapy remains the recommended first-line active treatment for amblyopia. Binocular gaming may be considered as an adjunct or alternative for children who are unable to comply with patching.
What is known: • Patching is an effective standard treatment for childhood amblyopia. • Evidence for binocular gaming compared with patching has been inconsistent.
What is new: • Binocular gaming shows short-term benefit, but patching is superior long term. • High-quality trials support patching as first-line; gaming may be an adjunct.
本研究的目的是系统地比较双目游戏与常规遮挡治疗对儿童弱视视力改善的影响。我们根据PRISMA 2020指南(PROSPERO CRD420251080735)进行了系统评价和荟萃分析。PubMed、Scopus、Cochrane Library和谷歌Scholar检索了截至2025年6月的3-18岁单侧弱视儿童的随机对照试验。主要结果是最佳矫正视力改善,用标准化平均差(SMD)表示。采用随机效应模型,根据治疗时间、样本量和患者特征进行亚组分析。9项随机对照试验,包括986名儿童,符合纳入标准。综合分析显示,双目游戏和打补丁之间无显著差异(SMD 0.05, 95% CI - 0.2 ~ 0.3, p = 0.68),存在显著异质性(I2 = 65%)。亚组分析揭示了时间依赖性效应:短时间试验(≤6周)有利于双目游戏(SMD = 0.35, 95% CI = 0.05-0.65, p = 0.02),中时间试验(8-12周)没有明显的益处,而长时间试验(bb0 12周)有利于补片(SMD = 0.47, 95% CI = 0.72 - 0.22, p)。结论:双目游戏可能提供短期益处,但有力的证据表明补片对长期结果更有利。在充分的屈光矫正后,传统的遮挡治疗仍然是弱视推荐的一线积极治疗方法。双眼游戏可以被认为是一个辅助或替代儿童谁不能遵守补丁。已知情况:•贴片是儿童弱视的有效标准治疗方法。•与打补丁相比,双目游戏的证据并不一致。创新点:•双目游戏显示出短期收益,但补丁更具有长期优势。•高质量的试验支持打补丁作为一线;游戏可能是一种辅助手段。
{"title":"Short- and long-term outcomes of binocular gaming versus patching in childhood amblyopia: a systematic review and meta-analysis.","authors":"Luksanaporn Krungkraipetch, Dutdao Supajitgulchai, Angkhana Assawaboonyadech, Warisanan Puranawit, Kitti Krungkraipetch","doi":"10.1007/s00431-025-06728-y","DOIUrl":"10.1007/s00431-025-06728-y","url":null,"abstract":"<p><p>The aim of this study is to systematically compare binocular gaming with conventional occlusion therapy for visual acuity improvement in childhood amblyopia. We conducted a systematic review and meta-analysis according to PRISMA 2020 guidelines (PROSPERO CRD420251080735). PubMed, Scopus, Cochrane Library, and Google Scholar were searched through June 2025 for randomized controlled trials in children aged 3-18 years with unilateral amblyopia. The primary outcome was best-corrected visual acuity improvement, expressed as standardized mean difference (SMD). A random-effects model was applied with subgroup analyses by treatment duration, sample size, and patient characteristics. Nine RCTs, including 986 children, met the inclusion criteria. Pooled analysis showed no significant difference between binocular gaming and patching (SMD 0.05, 95% CI - 0.2 to 0.3, p = 0.68) with substantial heterogeneity (I<sup>2</sup> = 65%). Subgroup analyses revealed time-dependent effects: short-duration trials (≤ 6 weeks) favored binocular gaming (SMD 0.35, 95% CI 0.05-0.65, p = 0.02), medium-duration trials (8-12 weeks) showed no significant benefit, while long-duration trials (> 12 weeks) favored patching (SMD - 0.47, 95% CI - 0.72 to - 0.22, p < 0.001). Larger, high-quality trials consistently supported patching. Publication bias analysis indicated small-study effects, with trim-and-fill suggesting the true effect may favor patching (adjusted SMD - 0.15).</p><p><strong>Conclusion: </strong>Binocular gaming may provide short-term benefits, but robust evidence indicates patching is superior for long-term outcomes. After adequate refractive correction, conventional occlusion therapy remains the recommended first-line active treatment for amblyopia. Binocular gaming may be considered as an adjunct or alternative for children who are unable to comply with patching.</p><p><strong>What is known: </strong>• Patching is an effective standard treatment for childhood amblyopia. • Evidence for binocular gaming compared with patching has been inconsistent.</p><p><strong>What is new: </strong>• Binocular gaming shows short-term benefit, but patching is superior long term. • High-quality trials support patching as first-line; gaming may be an adjunct.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"73"},"PeriodicalIF":2.6,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1007/s00431-025-06717-1
Giovanni Barone, Fiammetta Piersigilli, Mauro Pittiruti
Vascular access is a cornerstone of neonatal intensive care, yet current practice remains heterogeneous due to the lack of harmonized international guidelines. In this article, we present a position paper developed by a group of European experts - the Neonatal European Vascular Access Teams (NEVAT) - designed as a guide in planning, inserting, and maintaining vascular access in neonates. The position paper was developed using a not anonymous consensus method. Seven working groups prepared preliminary drafts on seven specific topics: peripheral venous devices, umbilical catheters, epicutaneo-cava catheters, ultrasound-guided central catheters, intraosseous access, peripheral arterial catheters, and infusion line management. The drafts were analyzed, modified, and validated through multiple rounds of open discussion, until full agreement was reached. The resulting position paper advocates a proactive, individualized, and standardized approach. Key elements include evidence-based selection of the device, structured preprocedural evaluation, maximal aseptic precautions, systematic use of ultrasound, securement with cyanoacrylate and semipermeable dressings, and structured post-insertion surveillance. Infusion line management emphasizes the use of closed systems, passive disinfection caps, and checklists. The NEVAT developed this position paper with the purpose of combining best evidence with expert agreement, so as to reduce variability in clinical practice, enhance safety, and improve neonatal outcomes, while encouraging multidisciplinary collaboration and family-centered care. What is Known: • Neonates are highly vulnerable to vascular access complications, but current practice is heterogeneous, with limited evidence-based guidance and significant variability across NICUs. What is New: • The NEVAT group provides the first European position paper on neonatal vascular access, aiming to improve homogeneity in device selection, insertion, and maintenance, promoting a safer and more consistent care.
{"title":"Vascular access in the newborn: a position paper of Neonatal European Vascular Access Teams (NEVAT).","authors":"Giovanni Barone, Fiammetta Piersigilli, Mauro Pittiruti","doi":"10.1007/s00431-025-06717-1","DOIUrl":"10.1007/s00431-025-06717-1","url":null,"abstract":"<p><p>Vascular access is a cornerstone of neonatal intensive care, yet current practice remains heterogeneous due to the lack of harmonized international guidelines. In this article, we present a position paper developed by a group of European experts - the Neonatal European Vascular Access Teams (NEVAT) - designed as a guide in planning, inserting, and maintaining vascular access in neonates. The position paper was developed using a not anonymous consensus method. Seven working groups prepared preliminary drafts on seven specific topics: peripheral venous devices, umbilical catheters, epicutaneo-cava catheters, ultrasound-guided central catheters, intraosseous access, peripheral arterial catheters, and infusion line management. The drafts were analyzed, modified, and validated through multiple rounds of open discussion, until full agreement was reached. The resulting position paper advocates a proactive, individualized, and standardized approach. Key elements include evidence-based selection of the device, structured preprocedural evaluation, maximal aseptic precautions, systematic use of ultrasound, securement with cyanoacrylate and semipermeable dressings, and structured post-insertion surveillance. Infusion line management emphasizes the use of closed systems, passive disinfection caps, and checklists. The NEVAT developed this position paper with the purpose of combining best evidence with expert agreement, so as to reduce variability in clinical practice, enhance safety, and improve neonatal outcomes, while encouraging multidisciplinary collaboration and family-centered care. What is Known: • Neonates are highly vulnerable to vascular access complications, but current practice is heterogeneous, with limited evidence-based guidance and significant variability across NICUs. What is New: • The NEVAT group provides the first European position paper on neonatal vascular access, aiming to improve homogeneity in device selection, insertion, and maintenance, promoting a safer and more consistent care.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"71"},"PeriodicalIF":2.6,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical studies have shown that Elexacaftor-Tezacaftor-Ivacaftor (ETI) improves lung disease and body weight in individuals with cystic fibrosis (CF); however, gastrointestinal system effects remain unclear. The purpose of this study was to evaluate exocrine pancreatic function using fecal elastase-1 (FE-1) levels in CF patients receiving ETI therapy and to assess changes in fat-soluble vitamin levels specifically within the pancreatic-insufficient (PI) subgroup. We retrospectively evaluated FE-1 levels before and during ETI treatment in the entire study group. Additionally, sweat chloride levels and growth parameters were assessed before and after follow-up ETI therapy in the entire study group. Also, vitamin A, D, E, PT, and INR levels were evaluated in PI patients before and after follow-up ETI treatment. The study included 20 pediatric CF patients with baseline FE-1 values. PI was present in 18 patients. The median age at the start of ETI therapy was 9.5 years (IQR 7.7-13.5; range 3-21 years). The median time between the baseline FE-1 test and the last FE-1 test was 12.0 months (IQR 12.0-19.5). The median FE-1 value before ETI therapy was 20.6 mcg/g (IQR 20.6-31.9), and after follow-up, 20.6 mcg/g (IQR 20.6-32.5) in 18 PI patients. Both PS patients maintained FE-1 levels ≥ 200 mcg/g before and after follow-up on ETI therapy. A significant increase in vitamin A levels was observed in PI patients, with a mean rise of 122.8 µg/L (p = 0.016). No significant change was observed in vitamin E levels (mean change 0.63 ± 4.14 µg/L; p = 0.304). Conclusion: In our study, no significant improvement in FE-1 levels was observed in pediatric CF patients receiving ETI therapy, whereas a substantial increase in vitamin A levels was found in patients with PI. These findings suggest that the effect of ETI therapy on pancreatic function may be limited and that its impact on exocrine pancreatic function should be further investigated. What is Known: • Exocrine pancreatic insufficiency is common in cystic fibrosis and is typically assessed using fecal elastase-1 (FE-1). • CFTR modulator therapies, especially ETI, improve respiratory and nutritional outcomes by targeting CFTR function, but their impact on pancreatic exocrine function in pediatric patients remains unclear. C What is New: • In this real-life pediatric cohort, no significant increase in FE-1 levels was observed during ETI treatment. • Despite improvements in CFTR function and nutritional status, these changes were not accompanied by recovery of pancreatic exocrine function.
{"title":"Role of elexacaftor-tezacaftor-ivacaftor therapy on fecal elastase-1 and fat-soluble vitamins in children with cystic fibrosis.","authors":"Sanem Eryilmaz Polat, Satı Özkan Tabakçı, Işıl Bilgiç, Çelebi Yıldırım, Hande Yetişgin, Meltem Kürtül Çakar, Gamze Akça Dinç, Ayyüce Aktemur Ünlü, Şule Selin Akyan, Salih Uytun, Murat Yasin Gençoğlu, Dilber Ademhan Tural, Gökçen Dilşa Tuğcu, Güzin Cinel","doi":"10.1007/s00431-026-06742-8","DOIUrl":"https://doi.org/10.1007/s00431-026-06742-8","url":null,"abstract":"<p><p>Clinical studies have shown that Elexacaftor-Tezacaftor-Ivacaftor (ETI) improves lung disease and body weight in individuals with cystic fibrosis (CF); however, gastrointestinal system effects remain unclear. The purpose of this study was to evaluate exocrine pancreatic function using fecal elastase-1 (FE-1) levels in CF patients receiving ETI therapy and to assess changes in fat-soluble vitamin levels specifically within the pancreatic-insufficient (PI) subgroup. We retrospectively evaluated FE-1 levels before and during ETI treatment in the entire study group. Additionally, sweat chloride levels and growth parameters were assessed before and after follow-up ETI therapy in the entire study group. Also, vitamin A, D, E, PT, and INR levels were evaluated in PI patients before and after follow-up ETI treatment. The study included 20 pediatric CF patients with baseline FE-1 values. PI was present in 18 patients. The median age at the start of ETI therapy was 9.5 years (IQR 7.7-13.5; range 3-21 years). The median time between the baseline FE-1 test and the last FE-1 test was 12.0 months (IQR 12.0-19.5). The median FE-1 value before ETI therapy was 20.6 mcg/g (IQR 20.6-31.9), and after follow-up, 20.6 mcg/g (IQR 20.6-32.5) in 18 PI patients. Both PS patients maintained FE-1 levels ≥ 200 mcg/g before and after follow-up on ETI therapy. A significant increase in vitamin A levels was observed in PI patients, with a mean rise of 122.8 µg/L (p = 0.016). No significant change was observed in vitamin E levels (mean change 0.63 ± 4.14 µg/L; p = 0.304). Conclusion: In our study, no significant improvement in FE-1 levels was observed in pediatric CF patients receiving ETI therapy, whereas a substantial increase in vitamin A levels was found in patients with PI. These findings suggest that the effect of ETI therapy on pancreatic function may be limited and that its impact on exocrine pancreatic function should be further investigated. What is Known: • Exocrine pancreatic insufficiency is common in cystic fibrosis and is typically assessed using fecal elastase-1 (FE-1). • CFTR modulator therapies, especially ETI, improve respiratory and nutritional outcomes by targeting CFTR function, but their impact on pancreatic exocrine function in pediatric patients remains unclear. C What is New: • In this real-life pediatric cohort, no significant increase in FE-1 levels was observed during ETI treatment. • Despite improvements in CFTR function and nutritional status, these changes were not accompanied by recovery of pancreatic exocrine function.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 2","pages":"72"},"PeriodicalIF":2.6,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}